Effects of intracoronary compared to intravenous abciximab administration in patients undergoing transradial percutaneous coronary intervention: A sub-analysis of the EASY trial

被引:10
作者
Bertrand, Olivier F. [1 ]
Rodes-Cabau, Josep [1 ]
Larose, Eric [1 ]
Nguyen, Can Manh [1 ]
Dery, Jean-Pierre [1 ]
Proulx, Guy [1 ]
Roy, Louis [1 ]
Poirier, Paul [1 ]
Costerousse, Olivier [1 ]
De Larochelliere, Robert [1 ]
机构
[1] Univ Laval, Hop Laval, Inst Univ Cardiol & Pneumol, Intervent Cardiol Labs, Ste Foy, PQ G1V 4G5, Canada
关键词
Abciximab; Intracoronary; Stent; Platelets; Transradial; ACUTE MYOCARDIAL-INFARCTION; PLATELET-RICH CLOTS; UNSTABLE ANGINA; ANGIOPLASTY; BOLUS; EPTIFIBATIDE; INFUSION; PCI;
D O I
10.1016/j.ijcard.2008.04.073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In the EASY trial, we have shown the clinical equivalence between abciximab bolus-only and abciximab bolus followed by 12-h infusion in a wide spectrum of patients after percutaneous coronary intervention (PCI). Some reports have suggested better outcomes following intracoronary (IC) abciximab administration compared to intravenous (IV) delivery. We sought to compare cardiac biomarkers release and early and late clinical outcomes after IC or IV abciximab bolus delivery. Methods: From 1005 patients randomized in the EASY trial and undergoing transradial coronary stent implantation, 208 received IC abciximab bolus and 797 received IV abciximab bolus. Route of administration was left to operators' discretion. Creatine Kinase-MB, and Troponin-T (Tn-T) were obtained immediately prior to angiography, 4-6 h after PCI and the next day. MACE (death, MI, TVR) rate was evaluated at 30 days, 6 months and 12 months. Results: There were more patients with acute coronary syndrome (75% vs 64%, P=0.004) and previous MI (53% vs 42%, P=0.005) in the IC group and more patients with >= 3 dilated sites in the IV group (2% IC vs 7% IV, P=0.03). After PCI, the extent of Tn-T and CK-MB release remained comparable in both groups. The MACE rate was 2% in both groups at 30 days, 9% in IC bolus vs 5% in IV bolus (P=0.04) at 6 months and 10% in IC bolus vs 9% in IV bolus (P=0.50) at 12 months. By multivariate analysis, IC abciximab bolus was not associated with better outcomes at 12 months compared to IV bolus (HR 1.07, 95% CI 0.82-1.35, P=0.62). Conclusion: Compared to IV abciximab administration, IC abciximab was not associated with less cardiac biomarkers release or better clinical outcomes after uncomplicated transradial PCI. Further studies are required in clinical scenarios including patients with higher thrombotic burden and/or occluded vessels as in primary and rescue PCI. (c) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:165 / 170
页数:6
相关论文
共 50 条
  • [31] Effects of Early Intracoronary Administration of Nicorandil During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
    Feng, Chunguang
    Liu, Yi
    Wang, Lulu
    Niu, Dongdong
    Han, Bing
    HEART LUNG AND CIRCULATION, 2019, 28 (06) : 858 - 865
  • [32] Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular functionThe randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI)
    Ingo Eitel
    Josef Friedenberger
    Georg Fuernau
    Annett Dumjahn
    Steffen Desch
    Gerhard Schuler
    Holger Thiele
    Clinical Research in Cardiology, 2011, 100 : 425 - 432
  • [33] Meta-Analysis of Prospective Randomized Controlled Trials Comparing Intracoronary Versus Intravenous Abciximab in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
    Shimada, Yuichi J.
    Nakra, Navin C.
    Fox, John T.
    Kanei, Yumiko
    AMERICAN JOURNAL OF CARDIOLOGY, 2012, 109 (05) : 624 - 628
  • [34] Clinical outcome of intracoronary versus intravenous high-dose bolus administration of tirofiban in diabetic patients undergoing primary percutaneous coronary intervention
    Ghonim, Ahmed A.
    Mostafa, Abdalla
    Emara, Ahmed
    Algazzar, Alaa S.
    Qutub, Mohammed A.
    CARDIOVASCULAR JOURNAL OF AFRICA, 2019, 30 (05) : 285 - 289
  • [35] A Randomized Double-Blind Placebo-Controlled Study Comparing Intracoronary Versus Intravenous Abciximab in Patients With ST-Elevation Myocardial Infarction Undergoing Transradial Rescue Percutaneous Coronary Intervention After Failed Thrombolysis
    Bertrand, Olivier F.
    Larose, Eric
    Bagur, Rodrigo
    Maes, Frederic
    Gaudreault, Valerie
    Noel, Bernard
    Barbeau, Gerald
    Dery, Jean-Pierre
    Pirlet, Charles
    Costerousse, Olivier
    AMERICAN JOURNAL OF CARDIOLOGY, 2018, 122 (01) : 47 - 53
  • [36] Effect of Intracoronary and Intravenous Administration of Tirofiban Loading Dose in Patients Underwent Percutaneous Coronary Interventions Because of Acute Coronary Syndrome
    Turkmen, S.
    Fettser, D. V.
    Cagliyan, C. E.
    Sercelik, A.
    Arystanova, A. G.
    Tekin, K.
    Balli, M.
    Batyraliev, T. A.
    Samko, A. N.
    Sidorenko, B. A.
    KARDIOLOGIYA, 2013, 53 (01) : 23 - 27
  • [37] Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials
    Piccolo, Raffaele
    Eitel, Ingo
    Iversen, Allan Zeeberg
    Gu, Youlan L.
    Dominguez-Rodriguez, Alberto
    de Smet, Bart J. G. L.
    Mahmoud, Karim D.
    Abreu-Gonzalez, Pedro
    Thiele, Holger
    Piscione, Federico
    EUROINTERVENTION, 2014, 9 (09) : 110 - 120
  • [38] Transradial versus Transfemoral Approach in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials
    Piccolo, Raffaele
    Galasso, Gennaro
    Capuano, Ernesto
    De Luca, Stefania
    Esposito, Giovanni
    Trimarco, Bruno
    Piscione, Federico
    PLOS ONE, 2014, 9 (05):
  • [39] Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
    Steinhubl, SR
    Kottke-Marchant, K
    Moliterno, DJ
    Rosenthal, ML
    Godfrey, NK
    Coller, BS
    Topol, EJ
    Lincoff, AM
    CIRCULATION, 1999, 100 (19) : 1977 - 1982
  • [40] Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)
    Dziewierz, Artur
    Siudak, Zbigniew
    Rakowski, Tomasz
    Kleczynski, Pawel
    Dubiel, Jacek S.
    Dudek, Dariusz
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 36 (03) : 240 - 246